Latest Dr. Reddy's Laboratories Ltd (RDY) Headline
Post# of 68
Posted On: 03/14/2014 8:02:17 AM
Latest Dr. Reddy's Laboratories Ltd (RDY) Headlines
FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 5:00PM CDT
Mallinckrodt's Xartemis XR was approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in patients requiring opioid treatment and for whom alternative therapies are inadequate, ineffective or are not tolerated.
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Shares of RDY Up 34.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 05, 11:07AM CST
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on September 5th, 2013 at $34.42. In approximately 6 months, Dr Reddys Laboratories has returned 34.25% as of today's recent price of $46.21.
Dr. Reddy's reports market availibility of US FDA approved Moxifloxacin Hydrochloride Tablets 400 mg
M2 - Wed Mar 05, 6:21AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) disclosed on Wednesday that it has unveiled its Moxifloxacin Hydrochloride Tablets 400 mg in bottle counts of 30 in the US market.
Dr. Reddy's Announces the Launch of Moxifloxacin Hydrochloride Tablets
Business Wire - Wed Mar 05, 1:22AM CST
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced today that it has launched Moxifloxacin Hydrochloride Tablets, 400 mg, a therapeutic equivalent generic version of Avelox(R) (moxifloxacin HCl) tablets 400 mg in the US market on March 04, 2014, following the approval by the United States Food & Drug Administration (USFDA).
Enter Biosimilars: 3 Stock Picks - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Feb 26, 12:13PM CST
According to a report from Frost & Sullivan, the global biosimilars space generated $1.2 billion in 2013.
Today’s Top Health Care Stories: Dr. Reddy’s Labs, Jazz, and Sanofi
Leo Sun, The Motley Fool - Motley Fool - Wed Feb 26, 8:09AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a quick look at three stocks -- Dr. Reddy's...
Dr Reddy's unveils Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 ml in two single-dose prefilled syringes
M2 - Wed Feb 26, 3:16AM CST
Pharmaceutical company Dr Reddy's Laboratories (NYSE:RDY) disclosed on Wednesday that it has introduced the Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 ml for subcutaneous use in the US market.
Dr. Reddy's Announces the Launch of Sumatriptan Injection USP, Autoinjector System
Business Wire - Tue Feb 25, 11:43PM CST
Dr. Reddy's Laboratories (NYSE: RDY) announced yesterday that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL For Subcutaneous Use, a therapeutic equivalent generic version of IMITREX STATdosePen(R) (sumatriptan succinate) 6 mg/0.5 mL in the US market on February 25, 2014, following the approval by the United States Food & Drug Administration (USFDA).
Akorn (AKRX) in Focus: Stock Moves 5.0% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:21AM CST
Akorn, Inc. (AKRX) was a big mover last session, as the company saw its shares rise by over 5% on the day.
Cellceutix to formulate the Brilacidin drug for ophthalmic and otitis infections at Dr Reddy's Laboratories
M2 - Tue Feb 25, 3:56AM CST
Biopharmaceutical company Cellceutix (OTCQB:CTIX) said on Monday that it has selected Dr Reddy's Custom Pharmaceutical Services (CPS) for the formulation of the former's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections, one of the most common pediatric illnesses and also a leading cause of conductive hearing loss.
Impax Posts Loss in 4Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 10:27AM CST
Impax reports loss in fourth quarter of 2013.
Actavis Up on Strong 4Q Earnings Beat - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Feb 21, 8:46AM CST
The company will update its guidance once the Forest Labs acquisition goes through.
Uptrend Call Working As Dr Reddys Laboratories Stock Rises 25.5% (RDY)
Comtex SmarTrend(R) - Wed Feb 19, 9:17AM CST
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on September 5th, 2013 at $34.42. In approximately 6 months, Dr Reddys Laboratories has returned 25.49% as of today's recent price of $43.20.
Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 8:50AM CST
Seattle Genetics reported 4Q13 net loss per share of 13 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents.
Dr. Reddy's Beats on Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:44AM CST
Dr. Reddy's reported 3Q of fiscal 2014 (ended Dec 31, 2013) earnings per ADS of 59 cents, beating the Zacks Consensus Estimate of 42 cents
Dr. Reddy's Q3 & 9 Months FY14 Financial Results
Business Wire - Tue Feb 11, 4:51AM CST
--Q3 FY14 EBITDA at Rs. 10.0 billion(YoY growth of 67%)
Mallinckrodt Beats Q1 Earnings, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 9:35AM CST
Mallinckrodt beats Q1 earnings estimates.
FDA Approves Mallinckrodt's Xartemis XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 5:00PM CDT
Mallinckrodt's Xartemis XR was approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in patients requiring opioid treatment and for whom alternative therapies are inadequate, ineffective or are not tolerated.
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Shares of RDY Up 34.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 05, 11:07AM CST
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on September 5th, 2013 at $34.42. In approximately 6 months, Dr Reddys Laboratories has returned 34.25% as of today's recent price of $46.21.
Dr. Reddy's reports market availibility of US FDA approved Moxifloxacin Hydrochloride Tablets 400 mg
M2 - Wed Mar 05, 6:21AM CST
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) disclosed on Wednesday that it has unveiled its Moxifloxacin Hydrochloride Tablets 400 mg in bottle counts of 30 in the US market.
Dr. Reddy's Announces the Launch of Moxifloxacin Hydrochloride Tablets
Business Wire - Wed Mar 05, 1:22AM CST
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced today that it has launched Moxifloxacin Hydrochloride Tablets, 400 mg, a therapeutic equivalent generic version of Avelox(R) (moxifloxacin HCl) tablets 400 mg in the US market on March 04, 2014, following the approval by the United States Food & Drug Administration (USFDA).
Enter Biosimilars: 3 Stock Picks - Analyst Blog
Swarup Gupta - Zacks Investment Research - Wed Feb 26, 12:13PM CST
According to a report from Frost & Sullivan, the global biosimilars space generated $1.2 billion in 2013.
Today’s Top Health Care Stories: Dr. Reddy’s Labs, Jazz, and Sanofi
Leo Sun, The Motley Fool - Motley Fool - Wed Feb 26, 8:09AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a quick look at three stocks -- Dr. Reddy's...
Dr Reddy's unveils Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 ml in two single-dose prefilled syringes
M2 - Wed Feb 26, 3:16AM CST
Pharmaceutical company Dr Reddy's Laboratories (NYSE:RDY) disclosed on Wednesday that it has introduced the Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 ml for subcutaneous use in the US market.
Dr. Reddy's Announces the Launch of Sumatriptan Injection USP, Autoinjector System
Business Wire - Tue Feb 25, 11:43PM CST
Dr. Reddy's Laboratories (NYSE: RDY) announced yesterday that it has launched Sumatriptan Injection USP, Autoinjector System 6 mg/0.5 mL For Subcutaneous Use, a therapeutic equivalent generic version of IMITREX STATdosePen(R) (sumatriptan succinate) 6 mg/0.5 mL in the US market on February 25, 2014, following the approval by the United States Food & Drug Administration (USFDA).
Akorn (AKRX) in Focus: Stock Moves 5.0% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:21AM CST
Akorn, Inc. (AKRX) was a big mover last session, as the company saw its shares rise by over 5% on the day.
Cellceutix to formulate the Brilacidin drug for ophthalmic and otitis infections at Dr Reddy's Laboratories
M2 - Tue Feb 25, 3:56AM CST
Biopharmaceutical company Cellceutix (OTCQB:CTIX) said on Monday that it has selected Dr Reddy's Custom Pharmaceutical Services (CPS) for the formulation of the former's defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections, one of the most common pediatric illnesses and also a leading cause of conductive hearing loss.
Impax Posts Loss in 4Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 10:27AM CST
Impax reports loss in fourth quarter of 2013.
Actavis Up on Strong 4Q Earnings Beat - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Feb 21, 8:46AM CST
The company will update its guidance once the Forest Labs acquisition goes through.
Uptrend Call Working As Dr Reddys Laboratories Stock Rises 25.5% (RDY)
Comtex SmarTrend(R) - Wed Feb 19, 9:17AM CST
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on September 5th, 2013 at $34.42. In approximately 6 months, Dr Reddys Laboratories has returned 25.49% as of today's recent price of $43.20.
Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 8:50AM CST
Seattle Genetics reported 4Q13 net loss per share of 13 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents.
Dr. Reddy's Beats on Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:44AM CST
Dr. Reddy's reported 3Q of fiscal 2014 (ended Dec 31, 2013) earnings per ADS of 59 cents, beating the Zacks Consensus Estimate of 42 cents
Dr. Reddy's Q3 & 9 Months FY14 Financial Results
Business Wire - Tue Feb 11, 4:51AM CST
--Q3 FY14 EBITDA at Rs. 10.0 billion(YoY growth of 67%)
Mallinckrodt Beats Q1 Earnings, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 9:35AM CST
Mallinckrodt beats Q1 earnings estimates.
(0)
(0)